Quest Diagnostics Sees Hospital Deal Growth as 2027 Medicare Cuts Loom

Quest Diagnostics (NYSE:DGX) expects continued strength in testing demand and its hospital partnerships, while preparing for a potential revenue hit in 2027 if Medicare laboratory payment cuts take effect, a company representative said during a discussion of the business.

The representative said Quest is seeing an active pipeline for hospital laboratory partnerships and physician outreach acquisitions. The company also expects its consumer testing business, though still a small share of revenue, to grow by more than 20% over the long term.

The transcript identifies every speaker as “Operator” and does not provide individual names or titles.

Hospital partnerships and acquisitions

Quest acquired the physician outreach businesses of OhioHealth, University Hospitals and Allina Health in 2024, according to the representative. The acquisitions helped the company gain market share, and Quest expects to pursue additional deals where it has access to a market but wants to capture more business.

Those acquisitions generally reach Quest’s enterprise margins relatively quickly after initial integration costs, the representative said. Under the model, lab work previously sent by affiliated physicians to a hospital transfers to Quest.

Quest also operates inpatient hospital laboratories through its Co-Lab business. Hospitals receive guaranteed savings, while Quest earns a guaranteed margin, the representative said. The company onboarded a partnership with Corewell covering more than 20 hospitals and expects it to generate approximately $250 million in revenue in 2026.

Co-Lab’s mature operating margin rate is expected to remain below Quest’s enterprise rate of roughly 16% to 17%, at about 12% to 13%. But the business requires little capital, making its return on invested capital attractive, the representative said. Corewell’s margins are improving after starting lower because of setup and integration costs.

The representative said conversations with health systems are increasing as financial pressures mount, although the pipeline for both Co-Lab partnerships and outreach acquisitions has been healthy for some time.

Medicare payment uncertainty

Quest has estimated that reinstatement of cuts under the Protecting Access to Medicare Act, or PAMA, at the beginning of 2027 could reduce overall revenue by about 1%, followed by an additional impact of approximately 30 basis points in 2028 and 2029. Medicare accounts for about 8% of the company’s business, the representative said.

Quest expects cost reductions and other actions to offset a portion, but not the majority, of the 2027 impact. The representative characterized the issue as confined to Medicare pricing and said the broader business remains healthy, with strong utilization and favorable pricing dynamics.

Quest is lobbying for the RESULTS Act, which the representative said would suspend the cuts until 2029 and establish a third-party data collection process. The representative criticized the existing collection methodology as insufficiently representative and said passage would likely require inclusion in broader health care legislation. The outcome remains uncertain, and PAMA cuts could be delayed again, the representative said.

Although the cuts could increase pressure on smaller laboratories and community hospitals, Quest has not yet seen a direct cause-and-effect increase in consolidation discussions, the representative said.

Consumer testing and new investments

Quest’s consumer business is growing by more than 30% this year and is running at an annual revenue rate above $300 million, while representing less than 3% of the company’s overall business, the representative said. About 25% to 30% is direct-to-consumer testing, with another 65% to 70% coming from partnerships with wellness and technology companies.

Those partnerships include Apple Health, through which consumers can order a panel of about 50 biomarkers and receive results in the app. Quest expects consumer growth to exceed 20% over the long term but did not provide a growth forecast for next year.

For its Haystack Oncology minimal residual disease test, Quest is pacing commercial efforts while it seeks reimbursement, including work with MolDX on Medicare Advantage reimbursement. The representative said testing volumes are increasing and cited Food and Drug Administration breakthrough designation, New York State approval and results from the DYNAMIC study.

Looking to 2027, Quest expects continued utilization strength but plans more spending on Project Nova, its order-to-cash modernization effort. Productivity initiatives under its Invigorate program are intended to offset some costs, the representative said.

About Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.